Role of Low-Molecular-Weight Heparin in Unexplained Recurrent Pregnancy Loss

RESnTEC, Institute of Research

Status: Completed

Conditions: Pregnancy Loss

Treatments: Drug: Low molecular weight heparin

Study type: Interventional

Funder types: Other

Identifiers

NCT06484634

LMWHDGKHAN

Details and patient eligibility

About

Using low-molecular-weight heparin (LMWH), outcomes such as live birth rate and the occurrence of pregnancy complications are some of the variables reported in some studies, with varying degrees of success. The present study aimed to compare the role of LMWH in unexplained recurrent pregnancy loss.

Enrollment: 175 patients

Sex: Female

Ages: 18 to 44 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Pregnant females between 18 and 44 years of age
• Gestational age above 8 weeks
• A history of ≥3 consecutive first trimester pregnancy losses

Exclusion criteria

• Patients with systemic lupus erythematosus
• Positive IgG and IgM anticardiolipin antibodies
• Positive for thrombophilia screening
• Any platelet function abnormality or a previous thromboembolic event requiring anticoagulant therapy (including heparin, aspirin or warfarin)
• Sensitive to acetylsalicylic acid, heparin, or warfarin
• Patients with any genetic, anatomical, or hormonal cause of recurrent pregnancy loss

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

175 participants in 2 patient groups

LMWH Group

Experimental group

Description:

Women received a daily dose of 40 mg of Low Molecular Weight Heparin subcutaneously.

Treatment:

Drug: Low molecular weight heparin

Control

No Intervention group

Description:

Women received the placebo in the form of a multivitamin tablet.